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Abstract 
BACKGROUND: OMERACT convened a pre-meeting to bring together patients, regulators, 
researchers, clinicians and consumers in order to build upon previous OMERACT drug safety 
work, with patients fully engaged throughout all phases.  
 
METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, 
and an overview of current efforts within and outside OMERACT to identify patient-reported 
medication safety concerns. On day 2, two working groups presented results; after each, 
breakout groups were assembled to discuss findings.  
 
RESULTS: Five themes pertaining to drug safety measurement emerged.  
 
CONCLUSION: Current approaches have failed to include data from the patient ?Ɛ perspective. A 
better understanding of how individuals with rheumatic diseases view potential benefits and 
harms of therapies is essential.  
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BACKGROUND 
Outcome Measures in Rheumatology (OMERACT) is an international initiative aimed at 
improving outcome measurement across rheumatologic conditions. Immediately prior to 
OMERACT 2018 biannual event, a special pre-meeting was convened entitled Improving Risk-
Benefit Assessment of Drugs, with an Emphasis on Patients and their Perspectives on May 13-
14, 2018 in Terrigal, New South Wales, Australia.  The meeting was designed to bring together 
stakeholders reflecting multiple perspectives to discuss current policies and approaches in 
patient-focused drug development, and review ongoing work by OMERACT and other initiatives 
in this area (1-4). Notably, as this meeting included representatives from multiple regulatory 
and pharmaceutical industries from around the world, it offered a unique opportunity to hear 
perspectives from around the world of the growing importance of patient engagement in 
regulatory affairs.  
While OMERACT has a legacy of work in this area, notable research over the past two 
years represented a fresh look at drug safety. Consistent with OMERACT principles, in this work 
patients were fully engaged as patient research partners (PRPs) throughout all phases of the 
work from conceptualization through interpretation of results.  
The specific aims of the meeting were to invite our PRPs to: 1) convene with multiple 
stakeholders to review ongoing global efforts in patient-focused drug development; 2) identify 
opportunities for co-learning and development of patient-centered methods to assess potential 
harms in rheumatology, oncology, and nephrology clinical trials; and 3) develop this white 
paper outlining key considerations for the development of core outcome sets and measures of 
patient-valued safety outcomes for use in RCTs.  
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METHODS 
Participants included 42 stakeholders (9 PRPs, 2 rheumatology fellows, 26 
clinician/researchers, 5 regulators, payers or industry scientists; some individuals contributed to 
multiple categories) and included new and returning OMERACT members. A professional scribe 
created visual representations of the discussions on a white board throughout the meeting. 
During the first day, a brief introduction to history of OMERACT, and current 
methodologies in terms of previous drug safety work was presented by OMERACT executive 
members along with an brief overview of the new OMERACT Filter 2.1(5, 6) approaches to core 
set development (Figure 1). Current patient-centered efforts to assess benefits and harms were 
presented from PRPs and regulatory representatives from the United States (US) Food and Drug 
Administration, Canadian Agency for Drugs and Technologies in Health, European Medicines 
Agency, Ministry of Health New Zealand and Pharmaceutical Benefits Advisory Committee of 
Australia. Colleagues from nephrology (7) and oncology (8) presented new patient-reported 
outcomes (PROs) querying side effects and adverse events in their fields. 
On the second day, two OMERACT working groups presented new results exploring 
patient attitudes and experiences with rheumatology therapies. The OMERACT Safety Group 
presented results from six focus groups with inflammatory arthritis patients in Canada, the US, 
and Australia regarding their experiences and considerations with DMARDs. The OMERACT 
Glucocorticoid Impact Group summarized work completed over the past two years including  
two literature reviews, a survey, and patient interviews used to inform an ongoing Delphi to 
prioritize patient-valued outcomes regarding steroid use in rheumatology. Following each 
presentation, breakout groups of 8-10 different stakeholders were assembled to discuss key 
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findings, implications, opportunities and identify additional work needed. The full group was 
reconvened, and a representative from each group summarized the discussion and key 
messages for all attendees. 
RESULTS 
 The initial presentations introduced attendees to KDZd ?Ɛlong-standing 
commitment to fully engaging PRPs as co-producers in the development and validation of 
outcome measures in rheumatology. Patient attendees then discussed the challenges many of 
them had faced understanding the relative benefits and harms of therapeutics, how discussions 
(or lack thereof) with providers influenced their perceptions of safety and effectiveness, and 
individual considerations regarding safety that reflected personal priorities and values. 
Consensus quickly emerged that the outcomes that clinicians and trialists who monitor safety in 
drug development often differ from those that patients value most. For example, patients 
taking methotrexate to control their disease often reported considerable impact of what are 
ŽĨƚĞŶƚĞƌŵƐ “ŶƵŝƐĂŶĐĞƐŝĚĞĞĨĨĞĐƚƐ ? ?ŵĞŶƚĂůĨŽŐ ?ŶĂƵƐĞĂĂŶĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƵƉƐĞƚ) on quality 
of life. In contrast,  clinicians are primarily concerned with pathophysiologic manifestations 
such as hepatotoxicity when monitoring the effects of treatment.     
 Next, examples of patient-centered safety monitoring strategies in nephrology and 
oncology were presented. A representative from the Standardised Outcomes in Nephrology 
(SONG) Initiative briefly summarized ongoing work to identify patient-valued core domain sets 
and measures for use in nephrology trials across a range of diseases. Similar to rheumatology, 
the nephrology community views current reporting of harms in RCTs as poorly defined, 
inadequate, unreliable and failing to capture the range of patient experiences. Adapted from 
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the OMERACT onion(5), SONG has a conceptual schema of a kidney that represents disease-
specific mandatory and discretionary outcomes they recommend be measured in trials(9).  
 While a PRO assessing potential harms is not yet available in rheumatology or 
nephrology, a measure has been developed and extensively validated in oncology(10). The US  
National Cancer /ŶƐƚŝƚƵƚĞ ?ƐPatient-Reported Outcomes version of the Common Terminology 
Criteria for Adverse Events (PRO-CTCAE) is comprised of a bank of 124 patient-reported items 
describing 78 symptomatic adverse events such as dysphagia, nausea, and sensory neuropathy 
in the context of cancer treatment(11, 12). Importantly, PRO-CTCAE moves beyond binary 
presence or absence of symptoms, and asks about frequency, severity, and interference with 
daily activities (where applicable) of each symptom. This represents a major advancement in 
more fully characterizing patient experiences. There was consensus among attendees during 
discussion following the presentation that it is important to fully capture relevant aspects of 
symptoms when designing a rheumatology safety PRO. The PRO-CTCAE item bank also allows 
investigators to tailor symptom queries based to a specific molecule or drug class, and 
separates treatment-related effects from overall disease burden. Importantly, the PRO-CTCAE is 
typically used for weekly reporting for treatment that is delivered during a defined  period, 
which could be applicable to weekly reporting in rheumatology trials but may not be feasible in 
rheumatology clinical practice, where treatment is generally over a longer period of time. 
 As presentations results presented by the OMERACT Safety and Glucocorticoid Toxicity 
Groups are described in detail elsewhere (Andersen KM et al 2018, Cheah JT et al 2018), below 
we summarize the overarching themes resulting from the small and large group discussions, 
and proposed pathways forward (Figure 2).  First, there was consensus that patients, their 
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families and caregivers often have differing priorities and expectations of benefits and harms 
from their clinicians and trialists. Discrepancies between patients and clinicians on what 
matters most were echoed by results from SONG, where patients once again reported higher 
concern about life impact (fatigue, negative emotions), while physicians reported greater 
concern about clinically-defined medical events (cardiac arrest, heart attack, stroke, heart 
failure)(13). Furthermore, in a cluster-randomized trial, oncologists who were provided with 
ƚŚĞŝƌƉĂƚŝĞŶƚ ?ƐWZK-CTCAE scores were significantly more likely to themselves report important 
symptomatic adverse events that patients reported (pain, anxiety, fatigue, anorexia, dysphagia, 
ĚĞƉƌĞƐƐŝŽŶ ?ƚŚĂŶŽŶĐŽůŽŐŝƐƚƐǁŚŽĚŝĚŶŽƚƌĞĐĞŝǀĞƚŚĞŝƌƉĂƚŝĞŶƚ ?ƐWZK-CTCAE scores(14). Thus, 
attendees agreed it is essential to consider multiple perspectives when identifying essential 
domains to include in core outcome sets. 
 Second, to capture the impact of safety events from the patient perspective, it is 
important to ask patients about the effect of medication-related symptoms on day-to-day life 
as the cumulative effects over time appear to be a key driver of patient priorities. It also may 
helpful for patients to ask their family and friends if they have noticed changes in their  
physical, emotional, and social function that are potentially treatment-related. Attendees 
acknowledged that clinicians are often reticent to discuss side effects when they perceive little 
can be done to attenuate these, especially when there are few or no therapeutic alternatives. 
 Third, some noted that capturing and quantifying the impact of side effects may be 
challenging. For instance, when a side effect is common, discussing the intensity and impact 
may be more meaningful to patients than simply describing the frequency or probability of 
occurrence. The PRO-CTCAE group noted that it was often important to adjust for baseline 
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symptoms to maximize differences in patient-reported adverse events. The possibility of also 
utilizing a  single item to assess overall benefit-harm item was discussed where a patient would 
be asked to rate whether the perceived benefit outweighed the impact on day-to-day life (i.e., 
Was it worth it?). 
 Fourth, perceptions of benefit versus harm likely vary among subgroups and depending 
on individual circumstances. This theme is a current focus of the OMERACT Contextual Factors 
Working Group. For example, a person who is financially responsible for family members may 
be willing to tolerate more treatment-related symptoms if the medication allows them to 
continue working as compared with someone who does not have others relying on their ability 
to work. Inclusion of patients with diverse characteristics in race and ethnicity, age, sex, socio-
economic status, and living situations is needed in future trials to better understand issues 
related to safety priorities and tolerability.   
 There also was general agreement that in drug trials, competing priorities may influence 
the willingness of patients to disclose safety events. Some patients may be willing to tolerate 
more risk or be less likely to report adverse events to remain enrolled in trials that offer the 
only access to treatment, or if they perceive the treatment is highly beneficial. 
CONCLUSION 
Robust systems for designing, conducting, and reporting safety events in rheumatology 
RCTs have been refined over many decades. However, to date, little attention has been given to 
understanding and measuring outcomes that matter most to patients. A better understanding 
is needed of how patients with rheumatic diseases view the relative benefits and potential 
harms of a treatment, in order to design and select more adequate outcome measures for 
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safety events monitoring. Such understanding can allow patients and clinicians to make 
informed choices about treatment and address longstanding challenges related to treatment 
initiation and long-term adherence. During the meeting, there was recognition that 
stakeholders view safety through multiple lenses. Indeed, the concept of safety seems 
inextricably linked to efficacy in that it is the relative balance of benefit and harm, rather than 
absolute frequency counts of symptoms, which may be most meaningful and informative to 
patients. 
A research agenda to address this knowledge gap and develop patient-centered tools 
will require heightened appreciation for the full range of patient experiences, concerns, and 
preferences. The OMERACT Safety Group is currently conducting focus groups with 
international groups of patients to better elucidate patient perspectives and core domains 
needed to develop a new tool or adapt existing ones, such as the PRO-CTCAE. It will also be 
important to identify ways to capture the cumulative negative impact of what have traditionally 
been viewed as  “nuisance side effects ? such as nausea and address the added resources 
required to enhance collection, analysis and interpretation of safety PROs. As with all OMERACT 
initiatives, it is essential that patients are fully engaged in the co-development and co-
production of this work.   
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